Prof Michael Hofman
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
597 Scholarly works
18 Projects
HIGHLIGHTS
2027
Research grants (ARC, NHMRC, MRFF)
Improving Prostate Cancer Outcomes by Integrating Novel Imaging and Targeted Therapy (Theranostics) for Personalised Medicine
2026
Journal article
Perioperative ctDNA as a prognostic biomarker in endometrial cancer - the CODEC study
DOI: 10.1016/j.tranon.2026.1028712023
Research grants (international)
An Accelerated Platform Using Lead-212 Targeted \03b1-Particle Therapy to Radically Improve Cancer Lethality of Prostate Cancer Theranostics Using Novel Targets and Better Understanding of Resistance: The Cancer Lethality Lead Collaboration
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2018
Journal article
Cold kit for prostate-Specific membrane antigen (PSMA) PET imaging: Phase 1 study of 68Ga-Tris (Hydroxypyridinone)-PSMA PET/CT in patients with prostate cancer
DOI: 10.2967/jnumed.117.1995542017
Journal article
Prostate-specific membrane antigen ligands for imaging and therapy
DOI: 10.2967/jnumed.116.1867672017
Conference Proceedings
Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
DOI: 10.1093/annonc/mdx370.002
RECENT SCHOLARLY WORKS
2026
Journal article
Germline CDK12 variants in aggressive prostate cancer.
DOI: 10.1158/2159-8290.CD-26-00842026
Journal article
Pre-therapeutic PSMA PET imaging biomarkers demonstrate prognostic value in patients undergoing [177Lu]Lu-PSMA therapy: a systematic review and meta-analysis
DOI: 10.1016/j.clgc.2026.1026282026
Journal article
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617
DOI: 10.1016/j.eururo.2025.08.0152026
Journal article
Clonal Hematopoiesis after177 Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
DOI: 10.1158/1078-0432.CCR-25-40012026
Journal article
Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial
DOI: 10.1016/S1470-2045(26)00120-82026
Journal article
Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy.
DOI: 10.2967/jnumed.126.2725312026
Journal article
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
DOI: 10.1016/S1470-2045(26)00091-42026
Journal article
Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer
DOI: 10.1038/s41585-025-01107-6